Melatonin regulates nitric oxide synthase expression in ischemic brain injury

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Nitric oxide (NO) production by three NO synthases (NOS) isoforms—iNOS, eNOS, and nNOS—plays critical roles in neurological function and disease.
• While iNOS is linked to neurodegeneration, eNOS is recognized for its protective functions.
• Understanding the modulation of these isoforms is crucial for developing therapeutic strategies for ischemic brain injury.

Purpose of the Study:

• To investigate the neuroprotective effects of melatonin in a rat model of ischemic brain injury.
• To determine how melatonin influences the expression levels of iNOS, eNOS, and nNOS following ischemic insult.

Main Methods:

• Adult male rats were subjected to middle cerebral artery occlusion (MCAO) to induce ischemic brain injury.
• Animals were treated with melatonin (5 mg/kg) or vehicle prior to MCAO.
• Brain samples were analyzed 24 hours post-occlusion using Western blot to quantify NOS isoform expression and infarct area.

Main Results:

• Melatonin treatment significantly reduced the infarct area in the ischemic brain.
• Vehicle-treated rats showed increased levels of iNOS and nNOS, whereas melatonin administration prevented this injury-induced elevation.
• eNOS levels decreased in vehicle-treated rats, but melatonin counteracted this reduction, preserving eNOS levels.

Conclusions:

• Melatonin demonstrates significant neuroprotective effects in ischemic brain injury.
• The observed neuroprotection is associated with melatonin's ability to modulate the expression of NOS isoforms, specifically preventing iNOS and nNOS upregulation and maintaining eNOS levels.
• These findings suggest that the regulation of NOS isoforms by melatonin is a key mechanism contributing to its neuroprotective actions.